For example, objective responses occurred in anti-PD-1/PD-L1 immunotherapies regardless of PD-L1 expression on tumor cells according to the post-hoc biomarker analysis in large-scale clinical trials4,32. The gene discussed is CD274; the disease is neoplasm.